MX2021008208A - Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. - Google Patents
Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.Info
- Publication number
- MX2021008208A MX2021008208A MX2021008208A MX2021008208A MX2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A
- Authority
- MX
- Mexico
- Prior art keywords
- tesofensine
- prader
- body weight
- reduction
- willi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con un método de reducción del peso corporal o hiperfagia en pacientes con síndrome de Prader-Willi que comprende administrar el compuesto activo Tesofensina o una sal farmacéuticamente aceptable del mismo, preferiblemente por la administración de una formulación de liberación controlada que comprende los compuestos activos de tesofensina y un bloqueador delta. La invención se relaciona además con composiciones farmacéuticas que comprenden más de 0.150 mg de Tesofensina o una sal farmacéuticamente aceptable de la misma y no más de 25 mg de Metoprolol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3029052A CA3029052A1 (en) | 2019-01-07 | 2019-01-07 | Tesofensine for reduction of body weight in prader-willi patients |
CA3058933A CA3058933A1 (en) | 2019-10-16 | 2019-10-16 | Tesofensine for reduction of body weight in prader-willi patients |
PCT/EP2020/050153 WO2020144146A1 (en) | 2019-01-07 | 2020-01-07 | Tesofensine for reduction of body weight in prader-willi patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008208A true MX2021008208A (es) | 2021-11-17 |
Family
ID=69165342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008208A MX2021008208A (es) | 2019-01-07 | 2020-01-07 | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220160658A1 (es) |
BR (1) | BR112021013463A2 (es) |
MX (1) | MX2021008208A (es) |
WO (1) | WO2020144146A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4151210A3 (en) * | 2020-01-10 | 2023-06-14 | Harmony Biosciences, LLC | Pyridine-carboline derivatives as mchr1 antagonists for use in therapy |
EP4138830A1 (en) * | 2020-04-22 | 2023-03-01 | Saniona A/S | Treatment of hypothalamic obesity |
WO2023161533A1 (en) * | 2022-02-28 | 2023-08-31 | Noema Pharma Ag | Triple uptake inhibitor for the treatment of atypical depression |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU228356B1 (en) | 1996-02-22 | 2013-03-28 | Neurosearch As | Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
AU2003282375A1 (en) | 2003-02-05 | 2004-08-30 | Ipca Laboratories Limited | Pharmaceutical compositions and process of production thereof |
DE102005034351A1 (de) | 2005-07-22 | 2007-01-25 | Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh | Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten |
US20070053983A1 (en) | 2005-09-06 | 2007-03-08 | Girish Jain | Extended release compositions of metoprolol succinate |
US20070092573A1 (en) | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
US8815285B2 (en) | 2006-03-28 | 2014-08-26 | Wockhardt Ltd. | Extended release dosage forms of metoprolol |
US20090324717A1 (en) | 2006-07-28 | 2009-12-31 | Farmaprojects, S. A. | Extended release pharmaceutical formulation of metoprolol and process for its preparation |
US8235632B2 (en) | 2010-05-14 | 2012-08-07 | Illinois Tool Works Inc. | Cargo bag valve deflector |
WO2012052834A2 (en) | 2010-10-21 | 2012-04-26 | Inventia Healthcare Private Limited | Multiple unit particulate system comprising metoprolol succinate |
KR101708538B1 (ko) | 2011-08-26 | 2017-02-20 | 욱크하르트 리미티드 | 심혈관 질환의 치료 방법 |
KR20140101391A (ko) | 2011-12-09 | 2014-08-19 | 욱크하르트 리미티드 | 심혈관 질환의 치료 방법 |
US9211271B2 (en) | 2012-02-16 | 2015-12-15 | Saniona A/S | Pharmaceutical compositions for combination therapy |
WO2015004617A1 (en) | 2013-07-09 | 2015-01-15 | Ranbaxy Laboratories Limited | Extended-release pharmaceutical compositions of metoprolol |
SG11201706899VA (en) * | 2015-03-03 | 2017-09-28 | Saniona As | Tesofensine, beta blocker combination formulation |
-
2020
- 2020-01-07 WO PCT/EP2020/050153 patent/WO2020144146A1/en active Application Filing
- 2020-01-07 US US17/420,181 patent/US20220160658A1/en active Pending
- 2020-01-07 BR BR112021013463-8A patent/BR112021013463A2/pt not_active Application Discontinuation
- 2020-01-07 MX MX2021008208A patent/MX2021008208A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20220160658A1 (en) | 2022-05-26 |
BR112021013463A2 (pt) | 2021-09-14 |
WO2020144146A1 (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
MY150682A (en) | Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
JP2012502047A5 (es) | ||
US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
JP2018522920A5 (es) | ||
MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
JP2016505050A5 (es) | ||
WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
WO2013032558A4 (en) | Products for anti-inflammation support | |
MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
EP2599487B1 (en) | Therapeutic agent or prophylactic agent for neuropathic pain | |
MX2011002177A (es) | Metodo para combatir efectos adversos que surgen del tratamiento antipsicotico. | |
JP2019509309A5 (es) | ||
KR100844256B1 (ko) | 리세드로네이트와 비타민 d를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법 | |
CN108472333B (zh) | 组合 | |
AU2002251763B2 (en) | Method for treating cancer | |
MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
WO2019098983A4 (en) | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation | |
MX2022002038A (es) | Composicion farmaceutica para el tratamiento del insomnio. |